Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is a conflicting literature on the association between the use of antihyperglycemic drugs and dementia risk. OBJECTIVE: The goal of this case-control study was to analyze the association between the use of antihyperglycemic drugs and dementia risk in patients followed in general practices in Germany. METHODS: This study included patients with type 2 diabetes mellitus who had received a first dementia diagnosis in 972 general practices in Germany between January 2013 and December 2017 (index date). Controls without dementia were matched (1:1) to cases by age, gender, index year, and physician. Two multivariate regression models were used to study the association between the use of antihyperglycemic drugs and dementia risk. Model 1 included all antihyperglycemic drugs prescribed to patients regardless of the prescription duration, whereas Model 2 only included the longest therapy prescribed to each patient. RESULTS: There were 8,276 diabetes patients with dementia and 8,276 diabetes patients without dementia included in this study. In Model 1, glitazones were associated with a decreased dementia risk (odds ratio [OR] = 0.80), whereas insulin was associated with an increased risk of developing the condition (OR = 1.34). In Model 2, metformin, prescribed as monotherapy (OR = 0.71) or as dual therapy with sulfonylureas (OR = 0.90), was associated with a decrease in the likelihood of subsequently being diagnosed with dementia. By contrast, the combination of basal insulin and bolus insulin (OR = 1.47) and premix insulin (OR = 1.33) were risk factors for dementia. CONCLUSION: Metformin and glitazones were negatively associated with dementia, while insulin was positively associated with dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“Dementia is a chronic condition that affects 5–7% of people aged ≥ 60 years worldwide [1].”
Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727
Depressive symptoms and risk of dementia: The Framingham Heart Study
Saczynski, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., & Au, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62138 · Cited by 488
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317 · cited 1×
“Glitazones belong to the family of peroxisome proliferator-activated receptor gamma (PPAR-(cid:2) ) agonists, drugs known to prevent the neuropathological and behavioral changes brought about by Alzheimer’s disease and other dementias [15, 25].”
HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing
Zheng, F., Yan, L., Yang, Z., Zhong, B., & Xie, W. (2018) · Diabetologia · doi:10.1007/s00125-017-4541-7 · Cited by 280
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12689 · Cited by 276
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis
Cheng, C., Lin, C.-H., Tsai, Y.-W., Tsai, C.-J., Chou, P.-H., & Lan, T.-H. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu073 · Cited by 167 · cited 1×
“Several studies have suggested that these drugs have a protective effect [7, 10, 11, 14, 15], whereas others have found that they have no significant impact on dementia risk [8, 12] or that they themselves are risk factors [8–10].”
Cited by
Wu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139
Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18306 · Cited by 106
Tian, S., Jiang, J., Wang, J., Zhang, Z., Miao, Y., Ji, X., & Bi, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3673 · Cited by 79
Mehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29
Pai, Y., Chen, I., Lin, J., Chen, X., Chen, H., Chang, M., Huang, J., & Lin, C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15918 · Cited by 26
Metadata
- Authors
- Bohlken, J., Jacob, L., & Kostev, K.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-10-30
- Volume
- 66
- Issue
- 2
- Pages
- 725-732
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2897088252
- Cited by
- 67
- References
- 8
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study. https://app.cochat.ai/papers/10.3233/jad-180808
- The paper
- Bohlken, J., Jacob, L., & Kostev, K. (2018). Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-180808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.